Loading company…
Progentos Therapeutics develops small-molecule medicines for chronic illnesses, including multiple sclerosis.
Based in Watertown, US, Progentos Therapeutics was founded in 2024 by Chris Loose and Sanjay Magavi. It is developing small-molecule drugs that target oligodendrocyte progenitor cells and aim to promote myelin regeneration for people with MS. Forbion led its USD 65 million Series A round in May 2024, joined by Alta Partners, Mission BioCapital, Longwood Fund, and Dolby Family Ventures. The funding will support its MS program and pipeline.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in